These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 19929851

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y, Cadot C, Fournier MA, Poirier D.
    Bioorg Med Chem; 2008 Feb 15; 16(4):1849-60. PubMed ID: 18035543
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS, Thole HH, Philippe JC, Pasqualini JR.
    Anticancer Res; 2004 Feb 15; 24(3a):1433-8. PubMed ID: 15274306
    [Abstract] [Full Text] [Related]

  • 7. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
    Laplante Y, Rancourt C, Poirier D.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):146-53. PubMed ID: 18812208
    [Abstract] [Full Text] [Related]

  • 8. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Vicker N, Lawrence HR, Allan GM, Bubert C, Smith A, Tutill HJ, Purohit A, Day JM, Mahon MF, Reed MJ, Potter BV.
    ChemMedChem; 2006 Apr 25; 1(4):464-81. PubMed ID: 16892382
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J, Husen B, Koskimies P, Hirvelä L, Kallio L, Saarenketo P, Thole H.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):216-24. PubMed ID: 19014997
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
    Kruchten P, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):154-7. PubMed ID: 18984028
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A, Klein T, Werth R, Kruchten P, Bey E, Negri M, Marchais-Oberwinkler S, Frotscher M, Hartmann RW.
    Bioorg Med Chem; 2010 May 15; 18(10):3494-505. PubMed ID: 20413314
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Bey E, Marchais-Oberwinkler S, Kruchten P, Frotscher M, Werth R, Oster A, Algül O, Neugebauer A, Hartmann RW.
    Bioorg Med Chem; 2008 Jun 15; 16(12):6423-35. PubMed ID: 18514529
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
    Bydal P, Auger S, Poirier D.
    Steroids; 2004 May 15; 69(5):325-42. PubMed ID: 15219411
    [Abstract] [Full Text] [Related]

  • 17. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, Bhoga U, Bey E, Müller-Vieira U, Messinger J, Thole H, Hartmann RW.
    J Med Chem; 2008 Aug 14; 51(15):4685-98. PubMed ID: 18630892
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, Fetzer L, Scherer C, Müller-Vieira U, Messinger J, Thole H, Hartmann RW.
    J Med Chem; 2008 Apr 10; 51(7):2158-69. PubMed ID: 18324762
    [Abstract] [Full Text] [Related]

  • 19. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
    Karkola S, Lilienkampf A, Wähälä K.
    ChemMedChem; 2008 Mar 10; 3(3):461-72. PubMed ID: 18224704
    [Abstract] [Full Text] [Related]

  • 20. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
    Möller G, Deluca D, Gege C, Rosinus A, Kowalik D, Peters O, Droescher P, Elger W, Adamski J, Hillisch A.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6740-4. PubMed ID: 19836949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.